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Abstract Biochemical characterisation of the interaction of
mdm2 protein with p53 protein has demonstrated that full-length
mdm2 does not bind stably to p53^DNA complexes, contrasting
with C-terminal truncations of mdm2 which do bind stably to
p53^DNA complexes. In addition, tetrameric forms of the
p53His175 mutant protein in the PAb1620+ conformation are
reduced in binding to mdm2 protein. These data suggest that the
mdm2 binding site in the BOX-I domain of p53 becomes
concealed when either p53 binds to DNA or when the core
domain of p53 is unfolded by missense mutation. This further
suggests that the C-terminus of mdm2 protein contains a negative
regulatory domain that affects mdm2 protein binding to a second,
conformationally sensitive interaction site in the core domain of
p53. We investigated whether there was a second docking site on
p53 for mdm2 protein by examining the interaction of full-length
mdm2 with p53 lacking the BOX-I domain. Although mdm2
protein did bind very weakly to p53 protein lacking the BOX-I
domain, addition of RNA activated mdm2 protein binding to this
truncated form of p53. These data provide evidence for three
previously undefined regulatory stages in the p53^mdm2 binding
reaction: (1) conformational changes in p53 protein due to DNA
binding or point mutation conceals a secondary docking site of
mdm2 protein; (2) the C-terminus of mdm2 is the primary
determinant which confers this property upon mdm2 protein; and
(3) mdm2 protein binding to this secondary interaction site within
p53 can be stabilised by RNA.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The tumour suppressor function of p53 is linked to its ac-
tivity as a stress-activated sequence-speci¢c DNA binding pro-
tein and transcription factor. The modulation of this function
of p53 can be controlled by both amino- and carboxy-termi-
nal regulatory domains, which identify at least two distinct
pathways playing rate-limiting roles in controlling p53. The
¢rst pathway operates in proliferating, undamaged cells and
involves regulation of p53 protein degradation. In normal
cells, p53 is regulated by cycles of synthesis and degradation
through the mdm2-dependent proteosome pathway. Mdm2
protein has a ubiquitin ligase-associated function [1] and its
binding within the N-terminal BOX-I domain of p53 directs
p53 nuclear export and degradation in the cytoplasm. The
inhibition of mdm2 protein function by low-molecular weight
peptides [2] or by monoclonal antibody (mAb) injection [3]
activates p53 protein function as a transcription factor in the
absence of DNA damage and pinpoints one rate-limiting
pathway that negatively regulates p53 function in normal
cells. A second pathway that regulates p53 function is a C-
terminal negative regulatory domain, which ensures p53 is
maintained in a low-a⁄nity DNA binding or latent state.
Modi¢cation of the C-terminal regulatory domain by peptides
[4^6] or by the intracellular synthesis of activating mAbs [7]
can induce p53-dependent gene expression and apoptosis.
That both the N-terminal and C-terminal regulatory domains
of p53 can be modi¢ed by peptides or antibodies that alter
p53’s speci¢c activity places emphasis on identifying cellular
enzymes that target these domains and modulate the function
of p53.
Studies on identifying the cellular factors that target these
two regulatory domains of p53 have identi¢ed two key phos-
phorylation site domains whose modi¢cation changes in re-
sponse to DNA damage. Following low levels of irradiation
injury to a cell, p53 protein can be activated as a transcription
factor without protein stabilisation [4] that is modulated in
part by increased phosphorylation at the C-terminal CK2
site at serine-392. The unusual feature of this upstream signal-
ing pathway is that it is resistant to an inhibitor of CK2,
identifying a CK2-independent pathway targets serine-392 in
response to DNA damage [8]. Higher levels of irradiation
damage to a cell can both stabilise p53 protein and activate
its function as a transcription factor and this stabilised form
of p53 protein has an elevated steady-state phosphorylation at
serine-15, the ATM/ATR/DNA-PK site [9]. The stabilisation
of p53 protein has a striking requirement for p300 protein [10]
and phosphorylation within the BOX-I domain at serine-15
can stimulate p300 binding to and acetylation of p53 protein,
suggesting that the primary role of serine-15 phosphorylation
may be to stabilise p53 via p300 binding. However, serine-15
phosphorylation can also reduce the binding of mdm2 protein
to p53 [9] and may play a role in reducing the rate of p53
degradation after high levels of irradiation damage. Thus, at
least two upstream kinase signaling cascades can modulate the
biochemical function of p53 as a transcription factor; one
pathway targets the C-terminus of p53 and regulates speci¢c
DNA binding and a second pathway targets the N-terminal
BOX-I domain of p53 and stimulates p300 protein binding
while reducing mdm2 protein binding to p53.
Given the central role of mdm2 protein in the control of
p53 function, studying the regulation of mdm2^p53 binding in
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vitro is therefore important for understanding the mainte-
nance of p53 protein stability following activation; particu-
larly relevant in view of the complexity of conformations that
p53 can adopt (including latent, active and inactive isoforms
[11,12]) and the multiple isoforms of mdm2 protein that can
be synthesised. Binding studies using p53 truncation mutants
[13] have shown that the minimum p53 binding site for mdm2
can be mapped to the ¢rst 50 amino acids of p53 and peptide
binding studies re¢ned this to between amino acids 18 and 23
[14]. Speci¢c contact sites on p53 important for mdm2 binding
and for transactivation were identi¢ed as Phe19, Trp23 and
Leu26 by crystal structure analysis [15]. Recent studies have
also identi¢ed two novel in vivo BOX-I phosphorylation sites
on p53 at serine-20 and threonine-18 that can disrupt mdm2
binding [12,16] and highlight the existence of a clustering of
regulatory phosphorylation sites within the BOX-I domain
that can modulate p53 protein^protein interactions. However,
there is a C-terminal element within p53 that controls p53
binding to mdm2, as C-terminal truncation mutants of p53,
with an intact N-terminal docking site, decrease association
with mdm2 [17^19].
Although the primary docking site for p53 on mdm2 is
contained within the N-terminal domain of mdm2 [15], an
independent function for the C-terminal RING-¢nger domain
on mdm2 was identi¢ed after showing that polyguanylic acid
(poly-G) binds speci¢cally to this domain on mdm2 [20], and
was suggested to participate in protein^protein interactions or
DNA binding [21]. However, little is known about the e¡ect
of RNA binding to this domain of mdm2 on subsequent in-
teractions between mdm2 and p53, nor the e¡ect of full-length
mdm2 protein binding to p53 protein. In an e¡ort to identify
novel regulatory interactions in the assembly of an mdm2
protein^p53 protein complex, quantitative BIAcore and en-
zyme-linked immunosorbent assay (ELISA) analyses of p53^
mdm2 interactions were used to determine the nature and
extent to which structural and conformational changes in
p53 control binding to mdm2, and to look at the e¡ect of
other factors that regulate conformationally sensitive associa-
tions between the two proteins.
2. Materials and methods
2.1. Construction of expression vectors for the production of p53 and
p53 deletion mutant proteins
Deletion mutagenesis of the human p53 gene and subcloning into a
T7.7 expression vector was carried out as described from a single-
stranded pBSK vector DNA containing the wild-type p53 gene [22].
Wild-type and a His175-substituted p53 were subcloned into pVL1393
baculovirus expression vector as described [11]. Amino- and carboxy-
terminal deletion mutants of p53 and full-length mdm2 were expressed
in Escherichia coli BL21 cells (0.5 l culture volumes) and p53 was
induced by the addition of IPTG (1 mM ¢nal concentration). Cells
were centrifuged at 10 000 rpm and the pellets were lysed on ice by
sonication, after being resuspended in 4 ml of bu¡er A (50 mM Tris^
HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA) containing 0.8 ml of a
protease inhibitor mix (10 mM pefabloc, 0.1 mg/ml leupeptin, 5 mg/ml
aprotinin, 10 mg/ml pepstatin, 8 mM EGTA, 5 mM EDTA, 50 mg/ml
trypsin inhibitor and 5 mM benzamidine; all inhibitors were obtained
from Boehringer Mannheim). Insoluble material was pelleted by cen-
trifugation and the supernatant was initially probed for the presence
of p53 protein by Western blotting using PAb240 (Fig. 1) and DNA
binding assays (as in [23]). The soluble proteins were further fraction-
ated on a 5 ml HiTrap-Heparin column (Pharmacia) equilibrated with
bu¡er A, and eluted in a gradient of bu¡er A from 0.15 M to 1.0 M
NaCl. Fractions from the HiTrap-Heparin gradient were assayed for
the presence of p53 by Western blotting probed with anti-p53 mAb
240, and for mdm2 with mAb 4B2. Fractions containing p53 or mdm2
were stored at 370‡C after the addition of glycerol to 10% (v/v). Full-
length p53 was expressed in Sf9 cells as described [11].
2.2. Immunological methods and reagents
All reagents were from Sigma unless indicated otherwise. Interac-
tion of the C-terminal deletion mutants of p53 with mdm2 protein
was carried out using a two-site ELISA by ¢rst coating wells with
CM5 polyclonal antibody (pAb) at 2 Wg/ml in carbonate bu¡er (pH
9.0) at 4‡C for 16 h. Wells were blocked with 3% bovine serum
albumin in phosphate-bu¡ered saline plus 0.1% Tween-20. This was
followed by titrating increasing amounts of deletion mutants
p53Cv30, Cv44, Cv67 and Cv79. Wells were then loaded with
mdm2 protein followed by mAb 4B2 and detected by the appropriate
secondary antibody linked to peroxidase (rabbit anti-mouse horserad-
ish peroxidase (HRP) from Dako).
In experiments to look at the interaction of mdm2 protein with the
p53 deletion mutant proteins, in the presence of poly-G, the ELISA
wells were ¢rst coated with mAb 4B2 (anti-mdm2) and treated essen-
tially as described above followed by mdm2 and then p53. In one set
of experiments, mdm2 protein was incubated with poly-G (10 mg/
well), followed by increasing amounts of p53 protein. In a second
set of experiments, increasing amounts of p53 protein were associated
with poly-G (1 mg/ml p53), before being added to wells containing
mdm2. Wells were then probed with CM5 pAb followed by the ap-
propriate secondary antibody linked to peroxidase (goat anti-rabbit
HRP).
2.3. BIAcore
Surface plasmon resonance (SPR) measurements were performed
using BIAcore (Pharmacia). The N-terminal anti-mdm2 mAb 4B2
was captured on a CM5 sensor chip surface by amine coupling as
described in the manufacturer’s instructions (Pharmacia Biosensor
AB) and used in subsequent experiments to reversibly bind mdm2
and mdm2 plus poly-G. p53 was passed across this surface and the
binding characteristics of di¡erent forms of p53 protein were deter-
mined. SPR response was measured in resonance units (RU) (for most
proteins, 1000 RU corresponds to a surface concentration of about
1 ng/mm2). HBS (10 mM HEPES, pH 7.6, 150 mM NaCl, 3.4 mM
EDTA and 0.05% BIAcore surfactant P20) was used as a bu¡er in this
system at a £ow rate of 5 ml/min.
3. Results
3.1. Conformational changes within p53 protein induced upon
DNA binding or by missense point mutation conceal the
mdm2 binding site on p53 protein
p53 protein truncation mutants and full-length, untagged
mdm2 protein were puri¢ed as described above. The activity
Fig. 1. Western blot of E. coli cell lysates expressing wild-type p53,
a 25 and 42 amino acid N-terminal truncated p53, and a 30, 44, 64
and 79 amino acid C-terminal truncation of p53. The Western blot
was probed with a p53-speci¢c mAb 241, followed by a HRP-tagged
rabbit anti-mouse secondary antibody.
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of full-length mdm2 protein in the p53 binding assays was
established using ELISA, where an increase in the levels of
mdm2 protein gave a corresponding increase in p53^mdm2
complex formation (Fig. 2). The stoichiometry of binding
(25 ng of mdm2 protein gives the maximal signal with 50 ng
of p53) suggests that a large majority of the mdm2 protein
from the bacterial preparation is active in binding to p53
protein. Surprisingly, however, this active fraction of mdm2
was unable to supershift p53^DNA complexes using an in
vitro DNA binding assay. Previous experiments have already
shown that tetrameric forms of p53 protein undergo a con-
formational change upon binding to DNA [23], so it is pos-
sible that the N-terminal BOX-I domain of p53 becomes con-
cealed upon DNA binding, thus precluding the binding of any
protein to the BOX-I domain of p53. However, the antibody
DO1, which shares an overlapping, but distinct, speci¢city
with mdm2 protein in the BOX-I domain [24,12], was able
to supershift the p53^DNA complex (data not shown).
The inability of full-length mdm2 protein to bind to p53^
DNA complexes contrasts with that previously published us-
ing GST-mdm2/C-terminal truncation mutants, where the
GST-mdm2vC-terminal mutant was able to bind to and
supershift p53 protein^DNA [2]. Nevertheless, the inability
of full-length, untagged mdm2 protein to supershift p53^
DNA complexes suggested to us one hypothesis whereby con-
formational changes within the p53 tetramer, induced upon
binding to DNA, concealed a secondary interaction site for
full-length mdm2 protein.
Quantitative ELISA and BIAcore were subsequently used
to determine whether conformational changes in p53 tet-
ramers could reduce the speci¢c activity of mdm2 protein in
a p53 protein binding assay. Firstly, in the ELISA format,
where mdm2 can stably bind to p53 protein, the addition of
oligonucleotide DNA can reduce the amount of mdm2 pro-
tein bound to p53 protein (Fig. 3). Although the reduction in
mdm2 protein binding to p53^DNA complexes data is not as
pronounced as that observed using the band shift assay where
there is no detectable mdm2^p53^DNA complex, it is well
established that the band shift assays can better stabilise pro-
tein^DNA complexes than that which can be observed in so-
lution. This is the predominant reason for the widespread use
of gel electrophoresis as a ‘ligand binding assay’ for sequence-
speci¢c eukaryotic transcription factors. Second, increasing
amounts of DNA also reduced the binding constant of
mdm2 protein for p53 protein in a BIAcore (Fig. 4) and
established the use of BIAcore as a very sensitive and quanti-
tative, ‘real-time’, assay to manipulate and de¢ne the speci¢c
activity of mdm2 protein. Together, these data are consistent
with the DNA band shift assay in establishing that p53^DNA
complexes are refractory to interaction with mdm2 protein.
As previous data have clearly established that mdm2 pro-
tein can interact stably with small peptides from the BOX-I
domain of p53 protein [14,15,2], it has been generally thought
that this is the primary, if not sole, determinant of the mdm2
protein^p53 protein interface. An independent assay was
therefore developed in attempts to test the hypothesis that
the conformation of the p53 tetramer is a critical determinant
in its interaction with mdm2 protein. The naturally occurring
mutant form of p53 protein (Arg175 to His175) is inactive for
sequence-speci¢c DNA binding despite being in the tetrameric
and PAb1620+ conformation [25]. These data indicate that
this mutant form of p53 is not ‘denatured’ as de¢ned by
oligomeric status and PAb1620 reactivity, but it has some
unde¢ned structural defect, as it remains inactive for se-
quence-speci¢c DNA binding. Using the ELISA, mdm2 pro-
Fig. 2. Binding of full-length recombinant mdm2 expressed in E.
coli cells to wild-type p53 expressed in Sf9 cells determined by two-
site ELISA. Both mdm2 and p53 were partially puri¢ed by heparin-
Sepharose chromatography as outlined in Section 2. A ¢xed amount
of p53 was captured in ELISA wells by Ab CM5 (10 ng) followed
by addition of increasing amounts of mdm2 (0^20 ng). Mdm2
bound to p53 was detected by an mdm2-speci¢c antibody 4B2, fol-
lowed by a HRP-tagged rabbit anti-mouse secondary antibody.
Fig. 3. E¡ect of increasing amounts of p53-speci¢c oligonucleotide
(p53CON) on p53 binding to mdm2 detected in a two-site ELISA.
A ¢xed concentration of oligonucleotide (50 and 100 Wg) was added
to increasing amounts of wild-type p53 (0^100 ng) expressed in and
partially puri¢ed from Sf9 cells. These aliquots of p53 were added
to ELISA wells containing ¢xed amounts of mdm2 captured by a
speci¢c anti-mdm2 mAb, 4B2, and p53 was detected by pAb CM5
and HRP-tagged goat anti-rabbit secondary antibody.
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tein binding interacted ine⁄ciently with this mutant protein
(Fig. 5), consistent with there being a secondary interaction
site on p53 protein for mdm2. Consistent with these ELISA
data, a recent report has been published showing that the
mutant form of p53 encoded by the His273 allele is defective
in mdm2-dependent ubiquitination in vitro and in vivo, fur-
ther con¢rming that mdm2 binding to p53 is conformationally
regulated by alterations in the structure of the p53 tetramer.
3.2. Deletion of the C-terminal tetramerisation domain of p53
destroys the mdm2 interaction site on p53
The previous data suggested the existence of a second, con-
formationally sensitive interaction site of mdm2 in the core
domain of p53. As such, we investigated whether perturbation
of the quaternary structure of p53 by progressive deletion of
p53’s C-terminus would also prevent mdm2 from forming a
stable complex with p53. Using ELISA, although deleting the
C-terminal 30 amino acids of p53 had little e¡ect on mdm2
binding (Fig. 6), deletion of 44, 64 and 74 amino acids re-
sulted in progressively reduced binding of mdm2 to p53 (Fig.
6) similar to that previously observed in immunoprecipitates
[17]. These data are supported by BIAcore (Fig. 7A).
3.3. Poly-G RNA enhances the binding of p53 truncation
mutations
The mdm2 protein contains a number of domains that are
likely to be involved in control of protein binding, with the N-
terminus known to contain the primary docking site for p53,
and an internal docking site present for the binding of ribo-
somal protein L5. However, the C-terminal RING-¢nger do-
main on mdm2 is also likely to be involved in the control of
the mdm2^p53 binding interface since homologous regions in
other proteins appear also to have roles in protein^protein
interaction or DNA binding [21]. Poly-G, a homopolyribonu-
cleotide RNA of about 400 bases, binds speci¢cally to the
RING-¢nger domain of mdm2 and deletion of this region
abrogates polynucleotide binding by mdm2 [20]. Data are
presented that show that RNA binding at the C-terminus of
Fig. 5. A p53Arg^His175 substitution mutant was recognised by Ab
DO1 but did not bind mdm2 in a two-site ELISA. p53His175 was
expressed in Sf9 cells and partially puri¢ed by heparin-Sepharose
chromatography as outlined in Section 2. Increasing amounts of
p53 (0^150 ng) were captured in ELISA wells by Ab CM5 (10 ng)
and probed with either p53-speci¢c mAb DO1 or ¢xed amounts of
mdm2 (20 ng), followed by mAb 4B2 and HRP-tagged secondary
antibody. This p53 mutant is refractory to sequence-speci¢c DNA
binding and represents an as yet undetermined structural mutation
of p53, signi¢cant in that this core domain mutation also appears
to a¡ect the ability of p53 to bind mdm2.
Fig. 6. Decreasing levels of binding of C-terminal p53 deletion mu-
tants (Cv30, Cv44, Cv64 and Cv79) to mdm2 by two-site ELISA.
A ¢xed amount of mdm2 (20 ng added) was captured in ELISA
wells by mAb 4B2 (10 ng) before the addition of increasing
amounts of each p53 C-terminal deleted protein. p53 was detected
by pAb CM5 and HRP-tagged goat anti-rabbit secondary antibody.
Even with an intact N-terminus, successive deletions at the C-termi-
nus of p53 abrogate mdm2 binding, indicating the importance of
this region of p53 in protein binding.
Fig. 4. p53 sequence-speci¢c DNA (PG) binding to wild-type p53
inhibits the subsequent binding of p53 to mdm2 in BIAcore. In-
creasing amounts of oligonucleotide (PG) (0, 10, 20, 40 Wg) bound
to p53 and blocked subsequent rapid binding of ¢xed amounts of
p53 (100 ng) to mdm2 in a dose-dependent manner. Mdm2 was ini-
tially bound to mAb 4B2 which had been linked to the surface of a
CM5 Biosensor chip. The histogram represents the maximum RU
for the association phase of p53 binding to mdm2, dissociation rates
of p53 from mdm2 were una¡ected by DNA.
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mdm2 may a¡ect the ability of mdm2 to associate with trun-
cated forms of p53.
Deletion of both the BOX-1 domain (p53Nv25) and trans-
activation domain (p53Nv42) almost entirely abrogates p53
binding to mdm2 in BIAcore (Fig. 7A), however, mdm2 with
captured poly-G resulted in a substantial increase in the rapid
binding of both N-terminal p53 mutant proteins to mdm2
(Fig. 7B), the binding of the transactivation domain truncated
p53 approaching that of wild-type p53 controls.
3.4. A p53 tetramerisation domain is required for rapid binding
to mdm2
The necessity for an intact p53 tetramerisation domain for
rapid binding to mdm2 was indicated in BIAcore where dele-
tion of 44 or 64 amino acids from the C-terminus of p53
almost completely abrogates binding to mdm2 (Fig. 7A).
However, in the presence of an mdm2^poly-G complex, the
p53Cv44 deletion bound to mdm2 at rates indistinguishable
from that of the full-length wild-type p53 (Fig. 7B), although
deletion of the tetramerisation domain in the p53Cv64 mutant
protein completely abolished binding to mdm2 in BIAcore
(Fig. 7A) even in the presence of an mdm2^poly-G complex
(Fig. 7B).
4. Discussion
There is detailed information about the mdm2 binding site
at the N-terminus of p53 which has shown that three amino
acid residues (Phe19, Trp23 and Leu26) are necessary for
binding at the BOX-1 region and that phosphorylation at
critical residues in this region can block this interaction. In
contrast, the present study shows that there is also a require-
ment for an intact tetramerisation domain (or association with
RNA) for mdm2 binding to p53 C-terminal truncation mu-
tants and describes the binding of mdm2 to p53 lacking a
BOX-1 domain. In broader terms, phosphorylation at the
C-terminus of p53 may also function not only to a¡ect the
conformational state of p53, from latent to an active confor-
mation, but also to control stability through the ability to
block the binding of mdm2, in a similar fashion as that
known to take place at the N-terminus. The C-terminal reg-
ulatory site of p53 has been shown to control its stability and
DNA binding function through phosphorylation by casein
kinase II and protein kinase C [11,4] and this may also a¡ect
the avidity of mdm2 binding in a similar way. In this study,
binding of either DNA or RNA by p53 has been shown to
inhibit the subsequent attachment of mdm2 in vitro, indicat-
ing that polynucleotide binding also involves a conformation-
al shift in p53 that blocks subsequent binding of mdm2. The
importance of the core domain in conformational regulation
of mdm2 binding was also shown by a mutant p53 with a
single histidine-175 substitution resulting in a disrupted core
domain that blocked mdm2 binding.
What is particularly interesting about this present work is
that not only does polynucleotide binding by p53 block mdm2
binding but that speci¢c RNA binding by mdm2 actually
enhances the association of mdm2 to a mutant form of p53
lacking seven amino acids of a complete tetramerisation do-
main (Cv44). This form of p53 is mAb 1620 negative in ELI-
SA, but may still have enough structural integrity to form a
dimer rather than a tetramer, and dimer formation has been
proposed to be su⁄cient for in vivo p53 activity [26]. How-
ever, deletion of the entire tetramerisation domain (Cv64) to
produce a monomeric form of p53 completely abrogates bind-
ing of mdm2 to p53. An in vivo function of mdm2-enhanced
binding to p53 by RNA may therefore be to target truncated
or mutant/misfolded forms of p53 for degradation.
Although there is no de¢nite function known for the C-
terminal RNA binding of the RING-¢nger domain of
mdm2, one can speculate from the functions proposed for
other proteins containing a similar domain. The Drosophila
inhibitor of apoptosis protein DIAP1 also contains a C-ter-
minal RING-¢nger domain, similar to that of mdm2, which
may negatively regulate its activity [27]. The mdm2 RING-
¢nger domain might also act as a regulator of some target
involved in apoptosis [28]. There is a precedence for this in
that the promyelocytic leukemia oncoprotein PML has been
shown to have a pro-apoptotic activity which is mediated
through its RING-¢nger domain [29]. Single-stranded RNA
viruses cause relocation of PML bodies to the cytoplasm
which results in resistance to serum starvation in infected cells
and decreased apoptosis. Viral RING-¢nger proteins (Z pro-
tein) also bind to PML and cause relocation of these nuclear
bodies to the cytoplasm [30], although Z protein binding to
PML is at the N-terminal region and does not require the
PML RING-domain for colocalisation.
Fig. 7. Poly-G RNA enhances the binding of p53 truncation muta-
tions to mdm2. (A) The p53 truncation mutants, Cv44, Cv64,
Nv25, Nv42 (100 ng), had minimal rapid binding to mdm2 in BIA-
core and compared to wild-type p53, the p53Cv30 mutation also
had decreased binding to mdm2 in the same assay. (B) Poly-G (5
Wg) precaptured by mdm2 bound to mAb 4B2 linked to the surface
of a CM5 Biosensor chip, enhanced the binding of all the p53 mu-
tations apart from p53Cv64, showing that a tetramerisation domain
is an absolute requirement for rapid binding of p53 to mdm2. The
histogram represents the maximum RU for the association phase of
p53 binding to mdm2.
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This work demonstrates the level of complexity involved in
the binding of mdm2 to p53. Not only can this be regulated
by phosphorylation at the N-terminus, but it is also dependent
on the conformational state of the protein, the presence of an
intact tetramerisation domain, the structure of the core do-
main and polynucleotide binding; all of which can act as
negative regulators of mdm2 binding and subsequent target-
ing for degradation.
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